Key result
Criterion 3 for abnormal Q waves (>3mm depth and/or >0.04s duration in ≥2 leads except aVR) was present in 27.6% of preclinical HCM carriers versus 5.4% of non-carriers (P<0.01).
Why the study?
Does a specific definition of abnormal Q waves accurately identify preclinical carriers of hypertrophic cardiomyopathy?
Population
148 genotyped subjects evaluated for hypertrophic cardiomyopathy (HCM)
Comparison
Application of Criterion 3 for abnormal Q waves vs Two other previously reported criteria for…
Design
Cross-sectional
Authors
Loading...
May support ECG screening in HCM families; leaves open prospective validation before clinical adoption.
Observational (n=148)
Does a specific definition of abnormal Q waves accurately identify preclinical carriers of hypertrophic cardiomyopathy?
Absolute Event Rate: 27.6% vs 5.4%
p-value: p=<0.01
A specific ECG criterion for abnormal Q waves (depth >3mm and/or duration >0.04s in ≥2 leads except aVR) provides the highest diagnostic accuracy for identifying preclinical carriers of hypertrophic cardiomyopathy.
Tetsuo Konno (2004) conducted an observational in Hypertrophic cardiomyopathy (n=148). Criterion 3 for abnormal Q waves (depth >3mm and/or duration >0.04s in ≥2 leads except aVR) vs. Non-carriers was evaluated on Presence of abnormal Q waves (p=<0.01). Criterion 3 for abnormal Q waves (>3mm depth and/or >0.04s duration in ≥2 leads except aVR) was present in 27.6% of preclinical HCM carriers versus 5.4% of non-carriers (P<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: